EASL 45th Annual Meeting (European Association for the Study of the Liver)

EASL 45th Annual Meeting
(European Association for the Study of the Liver)
April 14-18, 2010
Vienna, Austria



* New HCV Drugs EASL 2010 - (04/15/10)

* From Ash To Cure - EASL April 14-18 2010 - (04/21/10)

* Resistance Profile Of ABT-333 And Relationship To Viral Load Decrease In Patients Treated In Combination With Peg-interferon And Ribavirin For 28 Days. - (04/28/10)

* Pharmacokinetics of the HCV Polymerase Inhibitor ABT-333 in US and Japanese Healthy Volunteers - (04/28/10)

* Exposure-Viral Response Analyses of the Non-nucleoside Polymerase Inhibitor ABT-333, Following Monotherapy and ABT-333 Plus Pegylated Interferon and Ribavirin Therapy - (04/28/10)

* Pharmacokinetics of the HCV Polymerase Inhibitor ABT-072 Following Single and Multiple Dosing in Healthy Adult Volunteers - (04/28/10)

* Virologic Response Rates Following 4 Weeks of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Chronically-Infected HCV Genotype-1 Patients - (04/27/10)

* Genotypic Characterisation of Filibuvir Resistance in Patients Receiving Four Weeks Co-administration of Filibuvir with pegIFN/RBV(12 Week Analysis) - (04/27/10)

* Exposure-response Relationship of Filibuvir in HCV-infected Patients: Application to Dose Selection for Combination Therapy - (04/27/10)

* Impact of Sustained Virological Response After Antiviral Treatment in Chronic Hepatitis C Patients on Life Expectancy and Quality-adjusted Life-years - (04/27/10)

* Locteron, controlled-release interferon alpha 2b, 3 studies at EASL 2010 Vienna - 3 company press releases - (04/26/10)

* PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHRONIC HEPATITIS C GENOTYPE 1: FINAL RESULTS - (04/26/10)

* RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B + RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B + RIBAVRIN IN TREATMENT-NAïVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A) - (04/23/10)

* Slow Responders Benefit From 72 Weeks Peg/Rbv - Predicting Treatment Outcome Among Slow Responders: A Retrospective Analysis of the SUCCESS Study - (04/23/10)

* Q2week Controlled Release Interferon Alpha2b + Ribavrin Reduces Flu-like Symptoms >50% And Provides Equivalent Efficacy In Comparison To Weekly Pegylated Interferon Alpha2b + Ribavirin In Treatment-naïve Genotype-1 Chronic Hepatitis C: Results From EMPOWER, A Randomized Open-label 12-week Comparison In 133 Patients - (04/23/10)

* Early Viral Response Of Controlled-release Interferon Alpha2b And Ribavirin Vs. Pegylated-interferon Alpha2b And Ribavirin In Treatment-naïve Genotype-1 Hepatitis C: 12 Week Results (SELECT-2 Trial) - (04/23/10)

* IMPACT OF LOW-DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF DANOPREVIR (RG7227; ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE - (04/23/10)

* High Dose Pegasys/rbv can improve SVR: Impact of higher doses of peginterferon alfa-2a and ribavirin on RVR, cEVR and SVR in HCV G1 patients with viral loads ≥400 000 IU/mL weighing ≥85 kg - (04/23/10)

* Predictors of relapse among patients treated with standard- or induction-dose peginterferon alfa-2a (40KD) combined with standard- or higher-dose ribavirin in difficult-to-cure patients - (04/23/10)

* Pegasys vs Pegintron, Baseline characteristics and on-treatment predictors of responses from real-world patient cohorts: interim results of the multinational PROPHESYS cohorts - (04/23/10)

* Metabolic Syndrome (MS) [glucose/diabetes] Is a Negative Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: Results From the IDEAL Study - (04/23/10)

* Improved Inflammatory Activity With Low-Dose PegIntron (PEG) Maintenance Therapy in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program - (04/23/10)

* Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335 - (04/22/10)

* Preclinical characterization of non-covalent HCV NS3/4A protease inhibitor BI 201335 - (04/22/10)

* HBsAg Kinetics of Decay and Baseline Characteristics of HBeAg-Positive Patients with Chronic Hepatitis B Following 3 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment - (04/22/10)

* Evaluation of Potential Virologic Resistance in HBV Polymerase Among Subjects with Persistent Viremia Following up to 144 Weeks of Therapy with Tenofovir DF - (04/22/10)

* Efficacy of Tenofovir DF Treatment in Patients with a Suboptimal Response to Adefovir Dipivoxil - (04/21/10)

* Risk and Predictors of Mortality or Hepatocellular Carcinoma among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation - (04/21/10)

* Low Rates of Nucleos(t)ide-associated Adverse Events in the Long-term Experience with Entecavir - (04/21/10)

* MK-5172, the 1st HCV Protease Inibitor with Potent Acyivity Against Resistance Mutations In Vitro - (04/21/10)

* TMC435 & Drug Interactions: Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers - (04/21/10)

* EARLY ON-TREATMENT RESPONSES DURING PEGYLATED INTERFERON PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1) - (04/21/10)

* Combination of TMC435 with two novel NS5B inhibitors increases anti-HCV activity and results in a higher genetic barrier in vitro - (04/21/10)

* 4 week therapy with the non-nucleosidic polymerase inhibitor BI 207127 in combination with peginterferon alfa2A and ribavirin in treatment naïve and treatment experienced chronic HCV GT1 patients - (04/21/10)

* Pharmacokinetic-pharmacodynamic (PK-PD) analyses of TMC435 in treatment-naïve hepatitis C (HCV)-infected patients in the OPERA-1 study - (04/20/10)

* Once-daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-alpha-2a And Ribavirin Produces High Rates Of Extended Rapid Virologic Response In Treatment-naïve HCV-genotype 1 Subjects: Phase 2a Trial - Bristol-Myers Squibb Study AI444014 - (04/20/10)

* SILEN-C2: Early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (PegIFN/RBV) in chronic HCV genotype 1 patients with non-response to PegIFN/RBV - (04/20/10)

* Phase 2 Randomized, Double-Blind Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders with Chronic Hepatitis C Genotype 1: Final Report - (04/20/10)

* Nitazoxanide + Peg/Rbv in Nonresponders - (04/20/10)

* Combination of two complementary nucleotide analogues, PSI-7977 and PSI-938, effectively clears wild type and NS5b: S282T HCV replicons - Comparison with combinations of other antiviral compounds - (04/20/10)

* Sustained Virologic Response following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV Genotype 2/3 prior non-responders - (04/20/10)

* Vitamin D Supplement improve SVR in Chronic Hepatitis C (Genotype 1) Naïve Patients treated with Peg Interferon and Ribavirin - (04/20/10)

* Idenix Pharmaceuticals Reports Favorable Pharmacokinetic Data for IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C - (04/20/10)

* Idenix Pharmaceuticals Reports Positive Results With IDX184 nucleoside polymerase From Interim Analysis of Phase IIa Hepatitis C Study - (04/19/10)

* Triple Combinations of Direct-Acting Antiviral Agents Demonstrate Robust Anti-HCV Activity In Vitro - (04/19/10)

* Antiviral Activity, Pharmacokinetics & Safety of IDX184 in Combination with Peg/Rbv in Treatment Naïve Genotype 1 - (04/19/10)

* In Vitro Antiviral Activity of IDX320, a Novel and Potent Macrocyclic HCV Protease Inhibitor - (04/19/10)

* ANA598 HCV Polymerase Inhititor Safety & Activity + Peg/Rbv in Genotype 1 - (04/19/10)

* 72% OF PATIENTS RECEIVING ANA598 IN PHASE II COMBINATION STUDY WITH INTERFERON AND RIBAVIRIN ACHIEVE UNDETECTABLE LEVELS OF VIRUS AT WEEK EIGHT - (04/19/10)

* Idenix Pharmaceuticals Reports Favorable Pharmacokinetic Data for IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C - (04/19/10)

* Discrepancies Between Definitions of Null Response to Treatment with Peginterferon Alfa-2a and Ribavirin: Implications for New HCV Drug Development - (04/18/10)

* On-Treatment Response-Guided Therapy with Telaprevir q8h or q12h Combined with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C (Study C208) - (04/18/10)

* Activity of Telaprevir Alone or in Combination with Peginterferon Alfa-2a and Ribavirin in Treatment-naïve, Genotype 2 and 3, Hepatitis C Patients: Final Results of Study C209 - (04/18/10)

* On-Treatment Response-Guided Therapy with Telaprevir q8h or q12h Combined with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C (Study C208) - (04/18/10)

* Idenix Pharmaceuticals Reports Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study - (04/18/10)

* Silibinin as Rescue Therapy for Suboptimal Response to Peg/Rbv - (04/18/10)

* Vitamin D Improves SVR in Naïve Genotype 1 with Peg/Rbv - (04/16/10)

* InterMune Reports Virologic Response of Ritonavir-Boosted Danoprevir (RG7227/ITMN-191) in Patients with Chronic Hepatitis C - (04/16/10)

* Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Activity Against all HCV Genotypes - (04/16/10)

* Dose-Ranging, Three-Day Monotherapy Study of the HCV NS3 Protease Inhibitor GS-9256 - (04/16/10)

* Long-term Outcomes Following Combination Treatment with Boceprevir plus PegIntron/Ribavirin (P/R) in Patients with Chronic Hepatitis C, Genotype 1 (CHC-G1) - (04/16/10)

* Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Week 12 Sustained Virologic Response Rate - (04/16/10)

* GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV - (04/16/10)

* Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens - (04/15/10)

* Telaprevir in Null-Responders & Non-Responders - (04/15/10)

* VX-222 Vertex NNRTI Polymerase Inhibitor 3 Days Monotherapy - (04/15/10)

* Merck HCV Protease Inhibitor For Resistance - (04/15/10)